June 26, 2020 / 5:33 AM / 13 days ago

BRIEF-Allergan, An Abbvie Company, And Molecular Partners Receive CRL From FDA On Biologics License Application For Abicipar Pegol

June 26 (Reuters) - Abbvie Inc:

* ALLERGAN, AN ABBVIE COMPANY, AND MOLECULAR PARTNERS RECEIVE COMPLETE RESPONSE LETTER FROM FDA ON BIOLOGICS LICENSE APPLICATION FOR ABICIPAR PEGOL

* RATE OF INTRAOCULAR INFLAMMATION OBSERVED FOLLOWING ADMINISTRATION OF ABICIPAR PEGOL 2MG/0.05 ML RESULTS IN UNFAVORABLE BENEFIT-RISK RATIO

* ABBVIE PLANS TO MEET WITH FDA TO DISCUSS THEIR COMMENTS AND DETERMINE NEXT STEPS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below